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Abstract
Background Appetite loss has a major impact on cancer
patients. It is exceedingly prevalent, is a prognostic indicator
and is associated with inferior quality of life. Cachexia is a
multi-factorial syndrome defined by a negative protein and
energy balance, driven by a variable combination of reduced
food intake and abnormal metabolism. Not all cancer
patients that experience weight loss have appetite loss, and
the pathophysiology between cachexia and appetite loss
may thus be different. Knowledge of pathophysiology of
appetite loss in cancer patients is still limited. The primary
object of this study was to explore the association with 93
Please see Appendix 1 for details of the European Palliative Care
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predefined candidate single-nucleotide polymorphisms
(SNPs) and appetite loss in cancer patients to possibly
generate new theories of the pathophysiology of the
condition.
Methods A total of 1,853 cancer patients were phenotyped
according to appetite loss and then genotyped.
Results After allowing for multiple testing, there was no
statistically significant association between any of the SNPs
analysed and appetite loss. The ten most significant SNPs in
the co-dominant model had observed odds ratios varying
from 0.72 to 1.28.
Conclusions This large exploratory study could not find any
associations with loss of appetite and 93 SNPs with a
potential to be involved in appetite loss in cancer patients.
This does not however rule out genes putative role in the
development of the symptom, but the observed odds ratios
are close to one which makes it unlikely that any of the
individual SNPs explored in the present study have great
importance.
Keywords Anorexia . Appetite loss . Cachexia . Cancer .
SNP . Genetic
1 Background
Cachexia has a tremendous impact on survival and morbid-
ity in cancer patients [1]. It is presumed to account for 20 %
of cancer deaths due to cardiac and respiratory failure and
through immobility [2]. Cachexia is a multi-factorial syn-
drome defined by a negative protein and energy balance,
driven by a variable combination of reduced food intake and
abnormal metabolism [3].
Although loss of appetite may occur in some patients, it is
by itself not a defining symptom of cachexia. A significant
number of cancer patients who lose appetite do not undergo
weight loss and quite a few lose weight without having any
appetite loss [4, 5]. Consequently, the pathophysiology behind
weight loss and appetite loss may be different [6]. Appetite
loss is a key symptom in cancer patients: It is exceedingly
prevalent [7], is a prognostic indicator [8] and is associated
with inferior quality of life [9].
Appetite loss in cancer patients is sometimes divided into
primary and secondary anorexia. The pathophysiology be-
hind primary anorexia is still not well understood. It is
probably linked to both neurohormonal signalling pathways
(e.g. MC4R, serotonin), cytokines [e.g. interleukin-1 (Il-1),
tumour necrosis factor alpha (TNF-a)] as well as peripheral
appetite signals (e.g. ghrelin, NPY) [10]. Secondary anorex-
ia refers to symptoms that act as barriers to eating [11] for
instance nausea, xerostomia, depression and constipation.
When studying cancer anorexia and genetic polymorphisms,
there are challenges both in phenotyping the patients
correctly and in the possibility that both secondary and
primary anorexia may coexist.
Cancer cachexia is a very complex condition and thus
probably confines both a diverse pathophysiology and phe-
notype. It has been recognised that the assessment of ca-
chexia should include four domains, namely appetite loss/
reduced food intake, catabolic drive, muscle mass and
strength as well as functional and psychosocial impairment
[3]. By exploring appetite loss as a single factor that
contribute to the more complex syndrome of cachexia,
one might increase the probability of discovering geno-
types and thus the pathopyhysiology implicated in de-
veloping the condition. Knowledge of the mechanisms
behind cancer anorexia can suggest strategies for pre-
vention, diagnosis and therapy [12] of this widespread
and distressing symptom.
There is now growing evidence that appetite and re-
sponse to food in the general population is partly genetically
determined both in obese patients [13, 14] and in patients
with psychiatric eating disorders [15]. The impact of genetic
polymorphism to the propensity of developing anorexia in
cancer patients has only been evaluated in a few studies.
Three studies have found associations between appetite loss
and TNF-α [16], IL-β [17] and IL-10 [18] gene polymor-
phisms. In another study, a common mutation in the
melanocortin-4 receptor gene (MC4R) was not rendered
associated with changes in appetite [19]. None of the poly-
morphisms found associated with appetite loss in cancer
patients have been validated in other cohorts of cancer
patients (Table 1).
The primary objective of this study was to explore the
association between 93 predefined candidate single-nucleotide
polymorphisms (SNPs) and appetite loss in cancer patients to
possibly generate new theories of the pathophysiology of the
condition.
2 Methods
2.1 Patients and study design
Between February 2004 and April 2008, 2,294 cancer
patients were included in the European Pharmacogenetic
Opioid Study [20]. This was a multi-centre, cross-sectional,
observational study that included patients with cancer at
different sites, stages and with different performance status
who received opioid treatment. Patients were recruited at 17
centres in 11 different countries. Patients aged <18 years or
not capable of understanding the language used at the study
centre were not eligible.
The appropriate ethical authorities in all participating
centres approved the study protocol, and all patients gave
their oral and written informed consent.
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2.1.1 Clinical assessment
Age, ethnicity, gender, weight, height, Karnofsky per-
formance status and medication during the last 24 h
were recorded. Cancer diagnosis, presence of metastases
and time since the diagnosis of cancer were registered.
Body mass index was evaluated according to the WHO
scale. Information on survival was collected until Janu-
ary 2010. Patients’ subjective health at the time of
inclusion was measured by the European Organisation
for Research and Treatment of Cancer Core Quality of
Life Questionnaire, the EORTC QLQ-C30 version 3.0
[21]. In this questionnaire, the patients report symptoms
and functioning for the past week on a four-point verbal
rating scale: (1) not at all, (2) a little, (3) quite a bit and
(4) very much.
2.1.2 The phenotype for appetite loss
The patients were phenotyped as having anorexia/appetite
loss according to the EORTC QLQ-C30 questionnaire
(version 3.0) [21, 22], question 13: “have you lacked appetite”.
2.2 Blood sampling
Blood samples were collected at the time of inclusion and
stored at −80 °C before shipment to the Norwegian University
of Science and Technology (NTNU) in Trondheim, Norway
for DNA extraction.
2.2.1 Polymorphisms for exploratory analysis
Prior to the genetic analyses, 93 candidate SNPs from 27
genes were identified through literature review in 2009 as
having a putative impact on cancer anorexia pathophysiology.
These genes code for appetite regulation through inflamma-
tion (TNF, IL-1, Il-6, IL-1, interferon gamma [10], TLR4 [23],
hormones (melanocortin, ghrelin, leptin, cholecystokinin,
insulin-like growth factor and serotonin [10]) and neuractive
receptors (opioid mu receptor [24], cannabinoid receptor
[15]). Some SNPs were chosen due to their association with
appetite and obesity (peroxisome proliferator-activated recep-
tor gamma, adrenerg receptor [13]) (Online Table 1).
2.2.2 Genotyping and serum analyses
Genomic DNA extraction was performed at HUNT Biobank
(NTNU), Levanger, Norway. DNA was extracted from
EDTA whole blood using the Gentra Puregene blood kit
(Qiagen Science, Germantown, MD, USA).
Genotyping was performed using the SNPlex Genotyping
System according to the suppliers’ dry DNA protocol. The
Table 1 Previous publications on genetics and cancer anorexia
Author Polymorphism Population Phenotype OR/p values
Rausch-10 [18] IL-10 rs 3024498 (37 SNPs in 6
cytokine genes evaluated)
1149 Caucasian lung cancer
survivors
Lung Cancer Symptom Scale (1.04,1.46)
How much are you experiencing loss
of appetite?
Jatoi-09 [16] TNF-α RS800629 (22 cytokine
SNPs evaluated)
471 non-small cell lung cancer
patients
“How would you compare your appetite
now to what it was before your present
illness?”
0.46 (0.29,0.72)
Jatoi-07 [17] IL-1β-31: rs1143627 (4 IL-1 beta
polymorphisms evaluated)
44 patients with metastatic
gastric and gastroeosophagal
cancer
FACT-E
1. “I have a good appetite” 1. 0.02*
2. “I am able to eat the food I like” 2. 0.02*
Knoll-08 [19] ValI103Ile rs2229616
(One melanocortin-4 receptor
polymorphism evaluated)
509 patients (most lymphoma,
leukaemia and GI tumours)
Loss of appetite. The authors developed
a new semi structured interview
No associations
Assesed for eligibility
(n=2294)
Excuded (n=441)
Not European descent (n=61)
Incoplete phenotype data (n=345)
Missing blood sample (n=24 )
No SNPs recorded (n=6 )
Other (Greece) (n=5)
Analysed
(n=1853)
Fig. 1 Flowchart demonstrating enrolment
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capillary electrophoresis was carried out with an ABI 3730 48-
capillary DNA analyser. SNPlex signals were analysed using
the Gene Mapper version 4.0 software, followed by manual
reading. Samples giving low signals, which could not be
discriminated from the negative controls, were removed prior
to the analysis and treated as missing data. Genotype cluster-
ing was performed based on the SNPlex Rules 3730 method,
following factory default settings. Two SNPs, rs4680 and
rs1045642, which could not be analysed by the SNPlex
system, were genotyped at the HUNT Biobank (NTNU),
Levanger, Norway. They were analysed using TaqMan SNP
allelic discrimination by means of an ABI 7900HT. All
genotyping procedures were processed without regard of the
phenotype. All genotyping processes was performed accord-
ing to Applied Biosystems, Foster City, CA, USA
2.3 Statistical analyses
The possible associations with demographic- and disease-
related factors were investigated by uni- and multivariate
ordinal logistic regressions with appetite loss as the outcome
of interest. The factors explored were age, gender, kidney
disease, cancer site, Karnofsky status, presence of metastasis
and the use of antibiotics, steroids, chemotherapy or appetite
stimulants (dronabinol and megestrol) the last 24 h. Factors
significantly associated (p<0.05) with appetite loss in an
initial univariate analysis were included in the multivariate
analysis. Significant (p<0.05) factors from the multivariate
analyses were included as covariates in the genetic analyses.
The association between SNPs and appetite loss was ana-
lysed by ordinal logistic regression with appetite loss as the
outcome variable. All regression analysis was stratified by
country.
Analyses were also repeated without the inclusion of
covariates, as a sensitivity check. Before exploring the genetic
associations, SNPs were rejected if the genotypes were not in
Hardy–Weinberg equilibrium (HWE) (chi-squared test,
p<0.0005) or had minor allele frequencies (MAF) <5 %.
Three approaches were adopted to mitigate the multiplicity
issues. First, a false discovery rate of 10 % was used for
reporting the Benjamini–Hochberg (B-H) thresholds [25]. If
an SNP is to be classified as “significant”, its p value for
association should be below the B-H threshold. Second, the
co-dominant genetic model was pre-specified for the primary
analyses, with other models (dominant, recessive and additive)
being considered as exploratory analyses. A recessive trait will
only be expressed if the dominant allele is not present. In a co-
dominant model both alleles are visible in the phenotype, and in
an additive model, the two alleles have an enhancing effect on
each other’s influence on the phenotype. Third, interpretation of
p values was done with caution. STATAversion 11.0 was used
for all analyses (StataCorp. 2009 STATA Statistical Software:
Release 11. College Station, TX, USA, StataCorp LP).
3 Results
One thousand eight hundred and fifty-three patients with
complete data on genetic analyses and appetite score were left
for final analyses after excluding five patients fromGreece due
Table 2 Baseline characteristics (n01,853)
Gender Male 968 (52.2)
Female 885 (47.8)
Age 63 (18–91)
Department Hospitalised 1,458 (78.7)
Outpatients 395 (21.3)
Karnofsky Performance status 60 (20–100)
Body mass index 23.4 (9–45)
Tumour diagnosis Urologic 131 (7.1)
Lung 313 (16.9)
Breast 262 (14.1)
Prostate 225 (12.1)
Gastrointestinal 375 (20.2)
Pancreas 36 (1.9)
Female reproductive
organs
140 (7.6)
Head and neck 103 (5.4)
Hematological 100 (2.8)
Unknown origin 51 (2.1)
Sarcoma 49 (2.6)
Skin 38 (2.1)
Others 82 (4.4)
Metastasisa Liver 455 (24.6)
Bone 856 (46.2)
CNS 101 (5.5)
Lung 410 (22.1)
Other 731 (39.4)
None 302 (16.3)
Appetite loss Not at all 487 (26.3)
A little 484 (26.1)
Quite a bit 463 (25.0)
Very much 419 (22.6)
Switzerland 112 (6)
Germany 254 (13.7)
Denmark 28 (1.5)
Finland 29 (1.6)
UK 253 (13.7)
Iceland 145 (7.8)
Italy 392 (21.2)
Lithuania 54 (2.9)
Norway 470 (25.4)
Sweden 116 (6.3)
All numbers are absolute numbers or medians (range) if nothing else is
indicated. Percentages in brackets
aMany patients have more than one metastasis site
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to their low number, 61 patients of non-caucasian origin 345
patients due to incomplete data on appetite, 24 patients due to
missing blood samples and six patients due to no SNPs recorded
(Fig. 1). Out of the 1,853 patients left for analyses, 487 patients
had no appetite loss, 484 had a little appetite loss, 463 had quite
a bit appetite loss and 419 patients had very much appetite loss.
Patient demographics are presented in Table 2.
In order to find important covariates, variables potentially
associated with appetite loss were found based on clinical
experience and literature search. After applying first univariate
and thenmultivariate ordered regression analysis, eight factors
were retained as of prognostic importance for grade of appetite
loss. These were kidney disease, the use of antibiotics, use of
steroids, Karnofsky performance status, cancer originating
from female reproductive organs, head and neck cancer, me-
tastasis to liver and metastasis to bone. Age, gender, other
metastatic sites, other cancer diagnoses and some medications
were not significantly associated and were therefore not in-
cluded as prognostic factors in the subsequent genetic analy-
ses. Only 282 patients had used chemotherapy the last 24 h
and only 28 appetite stimulants; these low numbers may
account for the lack of statistical significant impact on appe-
tite, p00.055 and p00.57 respectively (Table 3).
The 93 candidate SNPs were genotyped in order to
identify new associations between appetite loss and genetic
polymorphisms. After 12 SNPs were excluded due to vio-
lation of HWE or for having a MAF <5 %, 81 candidate
SNPs remained for association analysis.
No SNPs were significantly associated with appetite loss
neither in the co-dominant, dominant, additive nor recessive
model. The ten most significant SNPs in the co-dominant
model are presented in Table 4, with observed odds ratios
varying from 0.72 to 1.28.
4 Discussion
For the last 10 years, there have been numerous publications
on the hereditability of appetite in both a psychiatric eating
disorders [15] and obesity [13]. There are only a few studies
looking at associations with appetite loss in cancer patients
and genetic polymorphisms [16–19]. The present study is
the largest study, both in number of patients and number of
polymorphisms looking at genetic variability associated
with appetite loss in cancer.
In this study, we did not find new associations with
appetite loss and polymorphisms with high theoretical
potential to be involved in the pathophysiology. The
SNP IL-1β-31:rs1143627 that has been found associated
with cancer anorexia in a previous study was not sig-
nificantly associated with appetite loss in the present
study [17]
It has, in several studies, been acknowledged that it is
notoriously difficult to validate polymorphism associated with
common diseases [26] . It is nowmore strongly recognised that
multiple testing and over-reliance on statistical p values results
in an excess of false positive associations. This is particularly
true when exploratory studies have a small sample size.
Table 3 Covariates retained in the genetic association analysis
Appetite loss Odds Ratio p value 95 % confidence
interval
Head and neck cancer 2.59 <0.001 1.73, 3.86
Female reproductive cancer 1.63 0.003 1.19, 2.24
Bone metastasis 0.81 0.015 0.68, 0.96
Liver metastasis 1.32 0.004 1.09, 1.60
Kidney disease 1.57 0.045 1.01, 2.43
Steroid use 0.74 <0.001 0.62, 0.87
Antibiotic use 1.33 0.006 1.09, 1.64
Karnofsky 0.54 <0.001 0.44, 0.65
Dependent variable is appetite loss. The p values and 95 % CI are from
multivariate analysis
Table 4 Ten most significant SNPs in the co-dominant model
SNP RS number p value (n01,853) B-H criterion OR
PPARG (peroxisome proliferator-activated receptor gamma) rs1801282 0.0039 0.0012 0.725
Postifng (interferon, gamma) rs2193049 0.0151 0.0025 1.238
PPARG (peroxisome proliferator-activated receptor gamma) rs3856806 0.0246 0.0037 0.783
IGF1 (insulin-like growth factor 1) rs11111272 0.3838 0.0049 0.832
CCKAR (cholecystokinin A receptor) rs3822222 0.0461 0.0062 1.230
IGFBP3 (insulin-like growth factor binding protein 3) rs3110697 0.0463 0.0074 0.819
IRS1 (insulin receptor substrate 1) rs2234931 0.0572 0.0086 1.284
CCKAR (cholecystokinin A receptor) rs7665027 0.0595 0.0099 1.219
GHRL (ghrelin) rs35681 0.0732 0.0111 1.169
IL10 (interleukin 10) rs1800872 0.0978 0.0123 0.863
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If the genetic effect is weak, both a validation study and
an explorative study would require very large sample sizes.
Thus, even when there is a true association, small-sized
studies will overestimate the effect sizes, sometimes grossly
so; that is the only way that a significant p value can be
achieved in an underpowered study.
If this study had been preformed analysing only a few
SNPs, there would probably had been several significant
findings. In the present study, we however endeavoured to
look at a large sample of patients and have used rigorous
statistical methods in order to address the multiplicity issues,
the heterogogenecity of different countries, and to take meas-
ures for clinical confounding factors. Strong and important
relationships between the tested SNPs and appetite loss in
cancer patients therefore seem unlikely. There are however
numerous SNPs within most genes, and there may still be
SNPs within these genes that are important for anorexia.
In genetic studies of common diseases, the capacity to
define genotypes is often far better than our capacity to
define phenotypes. This is a major concern when conduct-
ing and interpreting genetic association studies, and a study
looking at appetite is no exception to this. It cannot be ruled
out that the lack of association between the SNPs investi-
gated and appetite loss is due to the diagnostic tool used to
diagnose appetite loss in the present study. As there is no
universal agreement concerning the definition of appetite
loss, there are consequently challenges both in defining
and diagnosing anorexia. Anorexia and loss of appetite are
concepts often intermingled, as both can be defined as the
loss of desire to eat [7]. In the present study, we have chosen
not to differentiate between anorexia and appetite loss.
Anorexia can however also be considered conceptually su-
perior and consist of appetite loss, satiety, taste alterations,
altered food preferences [10], reduced food intake [27] and
even meat aversions or nausea/vomiting [7]. Appetite loss/
anorexia has been endeavoured diagnosed by visual ana-
logue scales and other patient recorded outcomes (e.g. AC/
S-12 or FAACT [27]). These assessments all measure slight-
ly different aspects of anorexia and have varying specificity.
In addition to this, appetite is often subjectively compared
with “normal” for a particular individual, yet there are no
thresholds to determine when anorexia becomes present,
and there are probably large individual differences. In addi-
tion, there is no critical duration of time when to consider
the appetite abnormal [10]. These are some of the factors
that make it difficult to establish true controls when studying
appetite. In the present article, the EORTC-QLQ-C30 ques-
tion “During the last week - have you lacked appetite?” have
been applied to define anorexia. Cancer patients with worse
scores on this question have in other studies demonstrated
significantly reduced survival [8] and more malnourishment
[28]. Another reason for choosing this phenotype is that it
has an inherent relation to the symptom in question. The
EORTC QLQ-C30 is also a well-validated assessment tool
that is translated to many languages.
Secondary anorexia is often defined as symptoms that act as
barriers to eating [11] (e.g., nausea, food intolerances and
constipation). The causes of secondary anorexia are sometimes
the same as the ones suggested contributing to appetite loss. In
the present exploratory study, it was therefore chosen not to
correct for secondary anorexia in the analysis as one might
remove the disease contributing gene (e.g. serotonin is also
implicated in depression and nausea [29]; IL-1 may also cause
fatigue, constipation and enhance pain [30]; and IL-6 is asso-
ciated to depression and fatigue [31]).
5 Conclusion
This large exploratory study could not find any associations
with loss of appetite and 93 SNPs with a potential to be
involved in appetite loss in cancer patients. This does not
however rule out genes putative role in the development of
the symptom, but the observed odds ratios are close to one
which makes it unlikely that any of the individual SNPs
explored in the present study have great importance.
In order to move forward in gaining new knowledge on
appetite loss in cancer patients, prospective studies with thor-
ough documentation of factors that influence appetite and
weight are warranted, as well as consensus on how to diagnose
anorexia. This is necessary in order to classify the patients
correctly. Unfortunately, there is today no patient-related out-
come tool that sufficiently provides this information.
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